Business Context and Reporting Period
This Form 8-K filing by SELLAS Life Sciences Group, Inc. (the "Company") reports on events occurring on July 12, 2018, and consummated on July 16, 2018. The filing details the entry into a material definitive agreement for an underwritten public offering and the execution of related warrant agreements.
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $24.2 million from the public offering, before deducting underwriting discounts, commissions, and offering expenses.
- Offering Price: $2.10 per share for common stock and accompanying warrants; $2.0999 per pre-funded warrant and accompanying warrant.
- Securities Issued:
- 6,845,000 shares of common stock.
- 4,675,000 pre-funded warrants (exercisable at $0.0001 per share).
- 11,520,000 common stock warrants (exercisable at $2.10 per share, expiring July 16, 2023).
- Preferred Stock Exchange: Holders of Series A 20% Convertible Preferred Stock have the right to exchange $7,871,186 of stated value and accrued dividends for 3,748,184 shares of common stock and warrants.
- Warrant Adjustment: Exercise price of warrants issued to Preferred Stock holders in March and May 2018 was adjusted from $6.59 to $2.10 per share.
Note: The filing does not provide specific data on revenue, net profit, operating cash flow, margins, or total debt levels as this is a current report regarding a capital transaction rather than a periodic financial statement.
Material Changes
The primary material change is the significant increase in the Company's capital base through the issuance of equity and warrant securities. Additionally, the Company updated its Risk Factors and Business descriptions previously filed in its 2017 Form 10-K to reflect current conditions.
Outlook, Risks, and Management Commentary
- Underwriters: Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. served as underwriters for the offering.
- Warrant Agent: Computershare, Inc. was appointed as the Warrant Agent.
- Risk Disclosures: The Company filed updated risk factors and business descriptions (Exhibits 99.1 and 99.2) to supplement prior disclosures.
- Unregistered Sales: Securities issued in exchange for Preferred Stock were issued pursuant to Section 3(a)(9), Rule 4(a)(2), and Regulation S under the Securities Act.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the extent of dilution resulting from the 11,520,000 new warrants and the potential conversion of 4,675,000 pre-funded warrants.
- Review the updated Risk Factors (Exhibit 99.1) for new material risks introduced by the capital raise.
- Assess the impact of the Preferred Stock exchange on the total outstanding share count.
- Monitor the Company's cash burn rate relative to the $24.2 million gross proceeds to determine runway extension.